Home Health Lancet pays attention to cardiovascular safety of Hanmi’s ‘Epeglenatide’

Lancet pays attention to cardiovascular safety of Hanmi’s ‘Epeglenatide’

by news dir

[FETV=김창수 기자] The world-renowned medical journal Lancet published a meta-analysis study including global clinical results, including the cardiovascular safety of Efpeglenatide, a biologic drug developed by Hanmi Pharm, in its October issue.

Efpeglenatide is a once-weekly dosage form biologic drug developed by Hanmi Pharmaceutical for the treatment of GLP-1 diabetes. It is based on the research results.

According to the published paper, Professor Navid Sata of the University of Glasgow, UK, and colleagues performed a meta-analysis of the cardiovascular benefit and risk ratio (HR) of GLP-1 receptor agonists in type 2 diabetes. The research team used clinical data from a total of 680 patients from 8 studies that met appropriate criteria, including cardiovascular mortality assessment, in studies in which more than 500 patients were enrolled among GLP-1 related papers published by June 2021.

The research team included the epeglenatide AMPLITUDE-O clinical trial in this study, further demonstrating the cardiovascular safety of GLP-1 drugs, as well as being the first exendin-4 based GLP-1 receptor agonist to develop 3-point MACE (cardiovascular disease). It has also been shown to reduce mortality, myocardial infarction, and stroke).

The research team found a statistically significant result that GLP-1 receptor agonists also reduced the hospital admission rate for heart failure in diabetic patients by 11%, suggesting the possibility of creating a new innovation for efeglenatide.

The researchers also confirmed that the once-weekly GLP-1 receptor agonist, such as efeglenatide, was nearly as effective as the daily treatment.

The epeglenatide AMPLITUDE-O clinical trial was led by Sanofi and is a phase 3 clinical trial announced at the American Diabetes Association (ADA) in June. This is a study in which 4mg or 6mg of efeglenatide was administered alone to 4076 patients with type 2 diabetes or cardiovascular disease in 344 regions in 28 countries. Compared to the placebo group, the incidence of major cardiovascular events was reduced by 27% and the incidence of kidney disease by 32%.

“It is significant that efeglenatide, one of the most widely used GLP-1 receptor agonists in the world, contributed to the encouraging results of this meta-analysis study,” said Kwon Se-chang, president of Hanmi Pharmaceutical. We will do our best to present the potential for creating new innovations for efeglenatide, which has secured cardiovascular safety as well as other benefits.”

.

Related Articles

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.